InterVenn Biosciences Appoints New Board Members
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- New Board Members: InterVenn Biosciences has appointed Alec Ford and Mitch Levine to its Board of Directors, aiming to advance the commercialization of glycoproteomic diagnostics and enhance the company's competitiveness in precision medicine.
- Alec Ford's Background: With over 30 years of experience in genomics and biotechnology, Alec Ford previously served as COO at Myriad Genetics, where he successfully launched new products and scaled business units, bringing valuable commercial growth expertise to InterVenn.
- Mitch Levine's Credentials: Mitch Levine is an accomplished finance and corporate strategist, having served as CFO at Oncocyte, where he led multiple capital raises and strategic acquisitions, and his extensive industry experience will help accelerate InterVenn's commercialization strategy.
- Strategic Implications: The restructuring of the board not only strengthens the company's leadership but also signals InterVenn's commitment to laying the groundwork for clinical applications of its glycoproteomic solutions, aiming to drive improvements in medical decision-making through innovation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
